Skip to main content

Advertisement

Table 2 Affected coronary artery status, treatment strategy, and pharmacological therapy at discharge

From: Low 1,5-anhydroglucitol levels are associated with long-term cardiac mortality in acute coronary syndrome patients with hemoglobin A1c levels less than 7.0%

  Survivor group (n = 189) Cardiac death group (n = 9) p -value*
Number of diseased vessel NS
 One, n (%) 80 (42.3) 2 (22.2)  
 Two, n (%) 54 (28.6) 3 (33.3)  
 Three, n (%) 55 (29.1) 4 (44.5)  
Stenosis of LMT, n (%) 15 (7.9) 2 (22.2) NS
Multi-vessel, n (%) 112 (59.3) 8 (88.9) NS
Target lesion NS
 LAD, n (%) 97 (51.3) 4 (44.5)  
 LCX, n (%) 32 (16.9) 0 (0.0)  
 RCA, n (%) 53 (28.1) 3 (33.3)  
 LMT, n (%) 7 (3.7) 2 (22.2)  
Treatment strategy NS
 PCI (BMS), n (%) 82 (43.4) 4 (44.5)  
 PCI (DES), n (%) 64 (33.9) 3 (33.3)  
 POBA, n (%) 14 (7.4) 0 (0.0)  
 CABG, n (%) 12 (6.3) 1 (11.1)  
Pharmacological therapy at discharge
Diuretics, n (%) 39 (20.6) 5 (55.6) 0.03
Anti-platelets, n (%) 188 (99.5) 9 (100) NS
Anti-coagulants, n (%) 15 (7.9) 2 (22.2) NS
CE inhibitor or ARB, n (%) 134 (70.9) 7 (77.8) NS
Beta-blocker, n (%) 133 (70.4) 6 (66.7) NS
Calcium-channel blocker, n (%) 52 (27.5) 1 (11.1) NS
Statin, n (%) 171 (90.5) 6 (66.7) NS
Oral hypoglycemic agents, n (%) 20 (10.6) 2 (22.2) NS
 Sulfonylurea, n (%) 5 (2.7) 1 (11.1) NS
 Alpha-glucosidase inhibitor, n (%) 9 (4.8) 0 (0.0) NS
 DPP-4 inhibitor, n (%) 8 (4.2) 2 (22.2) NS
  Metformin, n (%) 4 (2.1) 0 (0.0) NS
 Pioglitazone, n (%) 6 (3.2) 0 (0.0) NS
 Glinide, n (%) 0 (0.0) 0 (0.0) NS
Insulin, n (%) 2 (1.1) 0 (0.0) NS
Inotropic agents, n (%) 4 (2.1) 0 (0.0) NS
  1. Data are presented as number (percentage)
  2. LMT left main coronary trunk, LAD left anterior descending coronary artery, LCX left circumflex coronary artery, RCA right coronary artery, PCI percutaneous coronary intervention, BMS bare metal stent, DES drug eluting stent, POBA percutaneous old balloon angioplasty, CABG coronary artery bypass grafting, ACE angiotensin converting enzyme, ARB angiotensin-II receptor blocker, DPP-4 dipeptidyl peptidase-4
  3. * Comparisons between the survivor and the cardiac death groups